|
AstraZenecas Asthma Drug in Focus, Phase III Study Initiated
Zacks.com The phase III program will assess the safety and efficacy of tralokinumab in reducing the rate of asthma exacerbations in adults and adolescents suffering from severe, inadequately controlled asthma despite receiving inhaled corticosteroids plus long … |
View full post on asthma – Google News